Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Relative Bioavailability of a 2.5 mg Linagliptin / 1000 mg Metformin Fixed Dose Combination Tablet Administered With and Without Food to Healthy Male and Female Subjects in an Open, Randomised, Single-dose, Two-way Crossover, Phase I Trial

NCT02223026 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02223026
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02223026 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Relative Bioavailability of a 2.5 mg Linagliptin / 1000 mg Metformin Fixed Dose Combination Tablet Administered With and Without Food to Healthy Male and Female Subjects in an Open, Randomised, Single-dose, Two-way Crossover, Phase I Trial
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2010
Completion date
Not reported
Enrollment
32 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy